Home › Mga Problema sa Mata dahil sa Diabetes › Texas
Pag-aaral pangklinika para sa Mga Problema sa Mata dahil sa Diabetes sa Texas
5 pag-aaral para sa Mga Problema sa Mata dahil sa Diabetes ang naghahanap ng mga kalahok sa mga site sa Texas.
Mga Lungsod sa Texas
Opisyal na teksto ng pag-aaral (English)
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
- Austin Research Center for Retina ( Site 0033), Austin
- Austin Retina Associates ( Site 0008), Austin
- Retina Consultants of Texas ( Site 0001), Bellaire
- at 4 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07705555A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
- Texas Retina ( Site 0051), Arlington
- Texas Retina Associates ( Site 0055), Fort Worth
- Retina Consultants of Texas - Katy/Cinco Ranch ( Site 0100), Katy
- at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07705607A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
- Medical Center Ophthalmology Associates, San Antonio
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07588100Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
- Austin Research Center for Retina /ID# 276101, Austin
- Retina and Vitreous of Texas /ID# 283051, Bellaire
- Star Retina /ID# 276513, Burleson
- at 1 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT07592273A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
- Site 111, Abilene
- Site 129, Austin
- Site 130, Houston
- at 4 pa
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT07812090Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.